Date Prepared: May 2013
CURRICULUM VITAE
NAME:

Tatsuya Morimoto

OFFICE ADDRESS: 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
Phone: +81(54) 264-5763
Fax:+81(54) 264-5744

E-mail: morimoto@u-shizuoka-ken.ac.jp
EDUCATION:
2000

Ph.D. Graduate School of Medicine, Kyoto University

1992

M.D. Faculty of Medicine, Kyoto University

ACADEMIC APPOINTMENT:
2009-present

Professor and chairman
Division of Molecular Medicine, School of Pharmaceutical Sciences
University of Shizuoka, Shizuoka, Japan

2007-2009

Chief
Division of Translational Research
Kyoto Medical Center, National Hospital Organization, Kyoto, Japan

2004-2007

Chief
Laboratory of Molecular Cell Biology of Cardiovascular Disease
Research Institute for Production Development, Kyoto, Japan

2000-2004

Postdoctoral Fellow
Department of Cancer Biology
Dana-Farber Cancer Institute, Harvard Medical School, USA

LICENSURE:
1992

Medical License of Japan

SOCIETY MEMBERSHIPS:
Japanese Circulation Society (Specialist)
Japanese Society of Internal Medicine (Specialist)
Japanese Heart Failure Society (Councilor)
International Society for Heart Research, Japanese Section (Councilor)
The Japanese Pharmacological Society (Councilor)
Japanese Society of Anti-Aging Medicine (Councilor)
The Pharmaceutical Society of Japan (Councilor, Editor)
The Society of Cardiovascular Endocrinology and Metabolism
Japanese Association of Cardiovascular Pharmacology
Japanese Society of Molecular Medicine
International Society of Cardiovascular Pharmacotherapy,
Japanese Section (Secretary)
Asian Pacific Society of Cardiology (Fellow)
American Heart Association
European Society of Cardiology (Councilor)
World Heart Federation (Board)
American Nano Society
American Society of Nephrology
Great Wall International Congress of Cardiology

PUBLICATIONS
1. Katanasaka Y, Sunagawa Y, Hasegawa K, Morimoto T. Application of curcumin toheart failure therapy by targeting transcriptional pathway in cardiomyocytes. Biol
Pharm Bull. in press (Corresponding author)
2. Shimatsu A, Kakeya H, Imaizumi A, Morimoto T, Kanai M, Maeda S. ClinicalApplication of “Curcumin”, a Multi-Functional Substance Anti-Aging Medicine
2012;9 (1):43-51. (Corresponding author)
3. Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, Abe M, Ono K,Morimoto T, Fujita M, Shimatsu A, Takahashi Y, Hasegawa K. α1-Antitrypsin LowDensity-Lipoprotein Serves as a Marker of Smoking-Specific Oxidative Stress. J
Atheroscler Thromb 2012;19(1):47-58
4. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T,Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T.
A novel drug delivery system of oral curcumin markedly improves efficacy oftreatment for heart failure after myocardial infarction in rat. Biol Pharm Bull.
2012;35(2):139-44. (Corresponding author)
5. Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie H, Ono K, Takaya T, TakanabeMori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu
A, Hasegawa K. Distinct characteristics of circulating vascular endothelial growthfactor-A and C levels in human subjects PLoS ONE 2011;6(12):e29351.
6. ]Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H,Katanasaka Y, Kakeya K, Fujita M, Hasegawa K, Morimoto T. Innovative preparationof curcumin for Improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5.
(Corresponding author)
7. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S,Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. Anatural p300-specific histone acetyltransferase inhibitor, curcumin, in addition toangiotensin converting enzyme inhibitor exerts beneficial effects on left ventricularsystolic function after myocardial infarction in rats. Circ J. in press (Correspondingauthor)
8. Kaichi S, Takaya T, Morimoto T, Sunagawa Y, Kawamura T, Ono K, Shimatsu A,Baba S, Heike T, Nakahata T, Hasegawa K. Cyclin-dependent kinase 9 forms acomplex with GATA4 and is involved in the differentiation of mouse ES cells into
cardiomyocytes. J Cell Physiol. 2011;226(1):248-54.
9. Kaichi S, Hasegawa K, Morimoto T. Excessive apoptosis as a downstream molecular
event during the development of congenital heart diseases. Circ J. 2010;74(11):22978.
10. Fujita M, Sasayama S, Terasaki F, Mitani S, Morimoto T, Yamazaki T, Hayashi D,Kohro T, Okada Y, Nagai R; JCAD Study Investigators. Treatment effects of reninangiotensin system inhibitor and calcium channel blocker in patients with coronary
artery narrowing (from the Japanese Coronary Artery Disease Study). Heart Vessels.
2010;25(6):453-9.
11. Kitamoto M, Kato K, Sugimoto A, Kitamura H, Uemura K, Takeda T, Wu C, Nogaki
F, Morimoto T, Ono T. Sairei-to Ameliorates Rat Peritoneal Fibrosis Partly throughSuppression of Oxidative Stress. Nephron 2010;117(3):e71-e81.
12. Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono
K, Baba S, Yamanaka S, Nakahata T, Heike T. Cell line-dependent differentiation of
induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res.
2010;88(2):314-23.
13. Sunagawa Y, Morimoto T, Takaya T, Wada H, Kawamura T, Fujita M, Shimatsu A,
Kita T, Hasegawa K Cyclin-dependent kinsase-9 is a component of p300/GATA4complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J Biol
Chem. 2010;285(13):9556-68. (Corresponding author)
14. Morimoto T, Sunagawa Y, Fujita M, Hasegawa K Novel heart failure therapy
targeting transcriptional pathway in cardiomyocytes by a natural compound,curcumin. Circ J. 2010;74(6):1059-66. (Corresponding author)
15. Takaya T, Wada H, Morimoto T, Sunagawa Y, Kawamura T, Takanabe-Mori R,Shimatsu A, Fujita Y, Sato Y, Fujita M, Kimura T, Sawamura T, Hasegawa K. Left
Ventricular Expression of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1
in Failing Rat Hearts. Circ J. 2010 :25;74(4):723-9.
16. Wada H, Shinjo D, Kameda S, Ono K, Satoh N, Morimoto T, Osakada G, Nakano T,Fujita M, Shimatsu A, Hasegawa K Transmitral E/A ratio decreases in association
with abdominal fat accumulation in patients with impaired glucose tolerance or mild
diabetes without left ventricular hypertrophy. Heart Vessels. 2010;25(1):45-50.
17. Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, Fujita M,Shimatsu A, Kita T, Hasegawa K Aldosterone Signaling Associates withp300/GATA4 Transcriptional Pathway during Hypertrophic Responses inCardiomyocytes. Circ J. 2010;74(1):156-62. (Corresponding author)
18. Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, Nakano T, Fujita M,
Kita T, Shimatsu A, Hasegawa K Soluble VEGF receptor-2 is increased in sera ofsubjects with metabolic syndrome in association with insulin resistance.
Atherosclerosis. 2010;208(2):512-517.
19. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T,Shimatsu A, Hasegawa K MicroRNA-1 and MicroRNA-133 in spontaneous
myocardial differentiation of mouse embryonic stem cells. Circ J. 2009;73(8):1397-8.
20. Wada H, Abe M, Ono K, Morimoto T, Kawamura T, Takaya T, Satoh N, Fujita M,
Kita T, Shimatsu A, Hasegawa K. Statins activate GATA-6 and induce differentiatedvascular smooth muscle cells. Biochem Biophys Res Commun. 2008;374(4):731-6.
21. Morimoto T, Fujita M, Kawamura K, Sunagawa Y, Takaya T, Wada H, Shimatsu A,Kita T, Hasegawa K Myocardial Regulation of p300 and p53 by Doxorubicin
Involves Ubiquitin Pathways. Circ J. 2008;72(9):1506-11. (Corresponding author)
22. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda
M, Fujita M, Shimatsu A, Kita T, Hasegawa K: The dietary compound curcumin
inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. JClin Invest. 2008;118:868-78
23. Takaya T, Kawamura T, Morimoto T, Ono K, Kita T, Shimatsu A, Hasegawa K.
Identification of p300-targeted acetylated residues in GATA-4 during hypertrophic
responses in cardiac myocytes. J Biol Chem. 2008;283(15):9828-35
24. Wada H, Hasegawa K, Terashima S, Satoh N, Inoue M, Iida Y, Yamakage H,Kitaoka S, Morimoto T, Fujita M, Shimatsu A, Takahashi Y. Knowledge and interestregarding smoking-related health risks in smokers and non-smokers. Self-rating
depression scale score is a strong independent predictor of smoking cessation
outcomes Smoking Control Science 2008; 4: 4-8
25. Hosseinkhani M, Hasegawa K, Ono K, Kawamura T, Takaya T, Morimoto T, WadaH, Shimatsu A, Prat SG, Suemori H, Nakatsuji N, Kita T. Trichostatin A induces
myocardial differentiation of monkey ES cells Biochem Biophys Res Commun.
2007;356(2):386-91.
26. Fujita M, Morimoto T, Ikemoto M, Takeda M, Ikai A, Miwa K: Dose-dependency inpleiotropic effects of atorvastatin. Int J Angiol. 2007;16(3):89-91
27. Miyamoto S, Kawamura T, Morimoto T, Ono K, Kawase Y, Kita T, Hasegawa K
Histone acetyltransferase activity of p300 is required for the promotion of left
ventricular remodeling following myocardial infarction in adult mice in vivo
Circulation. 2006;113(5):679-90
28. Kawamura T, Ono K, Morimoto T, Wada H, Hirai M, Hidaka K, Morisaki T, Heike T,Nakahata T, Kita T, Hasegawa K. Acetylation of GATA-4 is involved in the
differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem.
2005;280(20):19682-8
29. Ehara N, Ono K, Morimoto T, Kawamura T, Abe M, Hasegawa K. The possible roleof peroxisome proliferator-activated receptor gamma in heart failure. Exp ClinCardiol. 9:169-173, 2004
30. Kawamura T, Hasegawa K, Morimoto T, Iwakura A, Nishina T, Nomoto T, Komeda
M. Down-regulation of Endothelin-1 and alteration of apoptosis signaling following
left ventricular volume reduction surgery in heart failure of adult rats. J Cardiovasc
Pharmacol. 2004;44 Suppl 1:S366-71.
31. Ehara N, Hasegawa K, Ono K, Kawamura T, Iwai-Kanai E, Morimoto T, Akao M,Adachi S, Kita T Activators of PPARgamma antagonize protection of cardiac
myocytes by endothelin-1 Biochem Biophys Res Commun. 2004;321(2):345-9
32. Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T, Hasegawa K FOG-2
competes with GATA-4 for a transcriptional coactivator p300 and represses
hypertrophic responses in cardiac myocytes. J Biol Chem. 2004;279(36):37640-50
33. Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N, Kita T,Hasegawa K Endothelin-1-dependent nuclear factor of activated T lymphocyte
signaling associates with transcriptional coactivator p300 in the activation of the B
cell leukemia-2 promoter in cardiac myocytes. Circ Res. 2004;94(11):1492-934. Kawamura T, Hasegawa K, Morimoto T, Iwai-Kanai E, Miyamoto S, Kawase Y, OnoK, Wada H, Akao M, Kita T Expression of p300 protects cardiac myocytes fromapoptosis in vivo. Biochem Biophys Res Commun. 2004;315(3):733-835. Yanazume T, Morimoto T, Wada H, Kawamura T, Hasegawa K Biological role ofp300 in cardiac myocytes. Mol Cell Biochem. 2003;248(1-2):115-9.
36. Yanazume T#, Hasegawa K, Morimoto T#, Kawamura T#, Wada H, Matsumori A,Kawase Y, Hirai M, Kita T. Cardiac p300 is involved in myocyte growth withdecompensated heart failure. Mol Cell Biol. 2003;23(10):3593-606. (#:equalcontributor)
37. Abe M, Hasegawa K, Wada H, Morimoto T, Yanazume T, Kawamura T, Hirai M,
Furukawa Y, Kita T. GATA-6 is involved in PPARgamma-mediated activation ofdifferentiated phenotype in human vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol. 2003;23(3):404-10.

38. Wada H, Hasegawa K, Morimoto T, Kakita T, Yanazume T, Abe M, Sasayama S.
Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription. JCell Biol. 2002;156(6):983-91.
39. Yanazume T, Hasegawa K, Wada H, Morimoto T, Abe M, Kawamura T, Sasayama S.
Rho/ROCK pathway contributes to the activation of extracellular signal-regulated
kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem .
2002;277(10):8618-25.
40. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, Sasayama
S: Calcineurin-GATA4 pathway is involved in β-adrenergic agonist-responsive
endothelin-1 transcription in cardiac myocytes. J Biol Chem. 2001.;276(37):34983-9.
41. Kakita T, Hasegawa K, Iwai-Kanai E,Adachi S, Morimoto T, Wada H, Kawamura
T,Yanazume T, Sasayama S. Calcineurin pathway is required for endothelin-1mediated protection against oxidant stress-induced apoptosis in cardiac myocytes.
Circ Res. 2001;88(12):1239-46.
42. Araki M, Hasegawa K, Iwai-Kanai E, Fujita M, Sawamura T, Kakita T, Wada H,Morimoto T, Sasayama S. Endothelin-1 as a protective factor against beta-adrenergic
agonist-induced apoptosis in cardiac myocytes. J Am Coll Cardiol. 2000;36(4):14118.
43. Wada H, Hasegawa K, Morimoto T, Kakita T, Yanazume T, Sasayama S: A p300
Protein as a Coactivator of GATA-6 in the Transcription of Smooth Muscle-Myosin
Heavy Chain Gene. J Biol Chem. 2000;275(33):25330-5.
44. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H,Yanazume T,Sasayama S:
Phosphorylation of GATA-4 is involved in α1-adrenergic agonist-responsive
transcription of the Endothelin-1 gene in cardiac myocytes. J Biol Chem.2000 :275:
13721-6
45. Kakita T, Hasegawa K, Morimoto T, Kaburagi S, Wada H, Sasayama S. p300 protein
as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic
factor gene. J Biol Chem.1999 :274:34096-102.
46. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. alpha- andbeta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat
cardiac myocytes. Circulation. 1999;100(3):305-11.
47. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Masutani H, Kitsis RN, Matsumori
A, Sasayama S. GATA-5 is involved in leukemia inhibitory factor-responsive
transcription of the β-myosin heavy chain gene in cardiac myocytes. J Biol Chem.
1999;274:12811-8.
48. Kaburagi S, Hasegawa K, Morimoto T, Araki M, Sawamura T, Masaki T, Sasayama
S. The role of endothelin-converting enzyme-1 in the development of alpha1adrenergic-stimulated hypertrophy in cultured neonatal rat cardiac myocytes.
Circulation. 1999;99(2):292-8.
49. Shiota T, Arizono N, Morimoto T, Shimatsu A, Nakao K. Trichomonas tenax
empyema in an immunocompromised patient with advanced cancer. Parasite.
1998;5(4):375-7.